QIAGEN Launches QIAsymphony SP Device Outside The U.S.
Zacks Investment Research | Oct 10, 2016 10:02PM ET
Molecular diagnostics major QIAGEN N.V. (NASDAQ:QGEN) recently announced the launch of QIAsymphony SP instrument as a front-end option for sample processing for its GeneReader NGS System outside the U.S. The GeneReader NGS workflow can now integrate with the system, allowing laboratories to perform processing of different samples. The processing and analysis is done to gain valuable molecular insights from samples comprising DNA, RNA and proteins from blood, tissue and other materials.
The GeneReader NGS workflow was launched by Qiagen last year. It is the world’s first complete Sample to Insight NGS (Next Generation Sequencing) solution designed for the delivery of actionable insights. NGS helps labs gain valuable molecular insights but has downsides such as high cost and fragmented workflow. The GeneReader NGS accurately identifies genetic markers (genes or DNA sequences) associated with approved therapies, leading professional guidelines and active clinical trials. It is presently available for sale outside the U.S.
QIAsymphony SP helps non U.S. labs perform sample processing with any difficulty. The instrument offers processing with continuous loading of up to 96 samples and proven protocols to process and purify samples for analysis. QIAsymphony SP is registered with the FDA and is part of workflows approved by the agency. It also offers advanced process control and integrates with Laboratory Information Management Systems (LIMS). The device is currently available for processing tissue samples for the GeneReader NGS System.
QIAGEN NV Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.